Abstract
Thermo Fisher Scientific has made an acquisition, will shutter a site in the U.K., and plans a pharma services facility in Germany. The acquisition of IntegenX adds a business with technology to rapidly generate forensic DNA profiles of crime suspects. In Ashford, England, Thermo Fisher will end lab-products manufacturing and R&D for plastic lab goods and move operations to facilities in Mexico, China, and Denmark. About 170 jobs are affected, the firm says. And in Rheinfelden, Germany, Thermo Fisher plans to build a $35 million pharma services facility to support customers doing clinical research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
